CKD Diagnostic Criteria
Chronic kidney disease is diagnosed when abnormalities in kidney structure or function persist for at least 3 months, specifically defined as eGFR <60 mL/min/1.73 m² and/or urine albumin-to-creatinine ratio (ACR) ≥30 mg/g (≥3 mg/mmol) and/or other markers of kidney damage such as hematuria or structural abnormalities. 1, 2
Core Diagnostic Requirements
The diagnosis requires TWO measurements over at least 3 months to establish chronicity 2. A single abnormal value does not confirm CKD—it could represent acute kidney injury or acute kidney disease rather than chronic disease.
Primary Diagnostic Parameters
Test both parameters simultaneously:
- eGFR <60 mL/min/1.73 m² (calculated using creatinine-based equations, preferably the 2021 CKD-EPI equation without race) 1, 2
- Urine ACR ≥30 mg/g (≥3 mg/mmol) measured in a spot morning urine sample 2
Either parameter alone is sufficient for diagnosis if persistent for ≥3 months, but both should always be measured for complete assessment 1, 3.
Additional Markers of Kidney Damage
CKD can also be diagnosed with normal eGFR (≥60 mL/min/1.73 m²) if other persistent abnormalities exist:
- Hematuria (after excluding urological causes)
- Structural abnormalities on imaging (reduced kidney size, cortical thinning, cysts, hydronephrosis)
- Pathological findings (fibrosis, atrophy on biopsy)
- Tubular disorders 1, 2, 3
Establishing Chronicity
Proof of chronicity can be established through:
- Review of past eGFR measurements showing persistent reduction
- Review of past albuminuria/proteinuria measurements
- Imaging findings (reduced kidney size, cortical thinning)
- Kidney biopsy showing fibrosis/atrophy
- Medical history of conditions causing CKD (diabetes, hypertension)
- Repeat measurements within and beyond the 3-month timeframe 4
Critical caveat: Do not assume chronicity from a single abnormal result—this could represent acute kidney injury requiring different management 4.
Enhanced Accuracy Testing
When creatinine-based eGFR may be inaccurate, measure cystatin C-based eGFR 2. The combined creatinine-cystatin C equation (eGFRcr-cys) provides superior accuracy and reduces racial/ethnic bias 1, 4.
Use cystatin C when:
- Abnormal muscle mass (very high or very low for age/sex)
- Drugs interfering with creatinine secretion
- More precise GFR assessment needed for clinical decisions
- Confirming low eGFR before major treatment decisions 2
Staging System
CKD is staged using the CGA system (Cause, GFR category, Albuminuria category) 2:
GFR Categories (G):
- G1: ≥90 mL/min/1.73 m²
- G2: 60-89 mL/min/1.73 m²
- G3a: 45-59 mL/min/1.73 m²
- G3b: 30-44 mL/min/1.73 m²
- G4: 15-29 mL/min/1.73 m²
- G5: <15 mL/min/1.73 m² (kidney failure)
Albuminuria Categories (A):
- A1: <30 mg/g (<3 mg/mmol) - normal to mildly increased
- A2: 30-300 mg/g (3-30 mg/mmol) - moderately increased
- A3: >300 mg/g (>30 mg/mmol) - severely increased
Common Pitfalls to Avoid
Don't diagnose CKD from a single measurement—always confirm with repeat testing after 3 months 2
Don't skip albuminuria testing—screening is severely underutilized, with less than half of diabetic patients screened annually in typical US practice 1
Don't use race-based eGFR equations—the 2021 CKD-EPI equation without race is now standard 1
Don't ignore temporary causes of abnormal results—dehydration, acute illness, medications, and urinary tract infections can cause spurious elevations in creatinine or albuminuria 1
Don't delay treatment while waiting for chronicity confirmation—if CKD is highly likely based on clinical context, initiate evidence-based treatments immediately 4
Risk Stratification
The combination of GFR and albuminuria categories determines risk for CKD progression and cardiovascular events 2, 5:
- Low risk: eGFR ≥60 with ACR <3 mg/mmol
- Moderate risk: eGFR ≥60 with ACR 3-30, OR eGFR 45-59 with ACR <3
- High risk: eGFR ≥60 with ACR >30, OR eGFR 45-59 with ACR 3-30, OR eGFR 30-44 with ACR <3
- Very high risk: eGFR <30 at any albuminuria level, OR eGFR 30-59 with ACR >30
This risk stratification directly guides treatment intensity and monitoring frequency 2, 5.